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Abstract: Consumption of fructose, the sweetest of all naturally occurring carbohydrates, has
increased dramatically in the last 40 years and is today commonly used commercially in soft drinks,
juice, and baked goods. These products comprise a large proportion of the modern diet, in particular in
children, adolescents, and young adults. A large body of evidence associate consumption of fructose
and other sugar-sweetened beverages with insulin resistance, intrahepatic lipid accumulation, and
hypertriglyceridemia. In the long term, these risk factors may contribute to the development of type
2 diabetes and cardiovascular diseases. Fructose is absorbed in the small intestine and metabolized in
the liver where it stimulates fructolysis, glycolysis, lipogenesis, and glucose production. This may
result in hypertriglyceridemia and fatty liver. Therefore, understanding the mechanisms underlying
intestinal and hepatic fructose metabolism is important. Here we review recent evidence linking
excessive fructose consumption to health risk markers and development of components of the
Metabolic Syndrome.
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1. Introduction
Food patterns and diet have greatly changed during the last decades in both industrialized
and developing countries together with sedentary lifestyle resulting in dramatic increases of obesity,
Metabolic Syndrome (MetS), non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes [1–4].
Importantly, the rapid increase in pediatric NAFLD has become the major concern globally [5,6].
As obesity is a driving force for NAFLD and type 2 diabetes, it is not surprising that the prevalence of
the MetS is high in both disorders.
The main component of dietary changes is not only lack of physical activity in face of extra calories,
but in particular increases of added sugar mainly in sugar sweetened beverages (SSBs). The common
sweeteners are sucrose (containing 50% saccharose and 50% fructose) and high fructose corn syrup
(containing up to 55% fructose). The consumption of SSBs, comprising fruit-flavored drinks and sport
and energy drinks, is the main source of added sugar. It accounts for about 15–17% of the total daily
energy intake in Western diets. Thus, it exceeds the recommended limit of 5% of added sugar (World
Health Organization’s guidelines 2018) [7]. Consequently, excess sugar consumption has become a
major public health problem particularly in children and teen-age populations globally. This menace
has initiated the call for the restriction of sugar consumptions [8].
There is substantial and consistent data evidence that exposure to excess fructose intake has
detrimental effects on multiple cardiometabolic risk factors [9–13]. In fact, fructose consumption is
considered to be a culprit in the MetS as a lipogenic compound that associates with excess ectopic
fat accumulation, particularly in the liver. This review will focus on the links between fructose
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consumption and the MetS, highlighting specifically effects of fructose on hepatic lipid homeostasis
and metabolism.
2. Metabolic Effects of Fructose Consumption
2.1. Fructose Metabolism in Enterocytes
Although fructose and glucose are both monosaccharides with closely similar formulas, their
metabolism pathways are divergent in both enterocytes and in hepatocytes [14–17]. Fructose absorption
is mainly mediated by glucose transporter 5 (GLUT-5), a fructose transporter expressed on the apical
border of enterocytes in the small intestine across the lumen in enterocytes (Figure 1) [17,18]. Fructose
trafficking from the enterocytes into the portal vein is partly also mediated by GLUT-2. Notably, a part
of fructose is metabolized in the cytosol by fructokinase, an enzyme that catalyzes the transfer of a
high-energy phosphate group to d-fructose. Notably, high flux of fructose into enterocytes induces
GLUT-5 expression. This mechanism may respond to excess chronic fructose intake by increasing the
capacity of the intestine for fructose absorption and transport to the liver. Thus, GLUT-5 activity is the
key regulator of fructose concentration in the portal vein.
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Figure 1. Metabolism of fructose in the intestine and liver. Fructose is in the small intestine 
metabolized by ketohexokinase (KHK) into fructose-1-phosphate (F-1-P) [19]. F-1-P is then cleaved 
by aldolase B into dihydroxyacetone phosphate and glyceraldehyde. Glyceraldehyde is 
phosphorylated by triokinase generating glyceraldehyde 3-phosphate (GAP). GAP and other triose 
phosphates are resynthesized into glucose via gluconeogenesis or metabolized into lactate or acetyl-
CoA, which are oxidized or used for lipogenesis. In the liver, fructose activates the transcription 
factors carbohydrate-responsive element-binding protein (ChREBP) and sterol regulatory element-
binding transcription factor 1c (SREBP1c) and their coactivator peroxisome proliferator-activated 
receptor-β (PGC1β) [16]. This results in upregulation of pathways that stimulate fructolysis, 
glycolysis, lipogenesis, and glucose production. Collectively, this results in increased hepatic glucose 
production, generation of lipid intermediates that may affect hepatic insulin sensitivity, increased 
expression of APOC3 and increased secretion of triglyceride-rich very-low density lipoproteins 
(VLDL). The increased APOC3 expression induces increased plasma apoC-III, an inhibitor of 
lipoprotein lipase and hepatic clearance of lipoprotein remnants [20]. This results in 
hypertriglyceridemia and accumulation of atherogenic triglyceride-rich lipoprotein (TRL) remnants. 
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by ket hexokinase (KHK) i to fructose-1-phosphate (F-1-P) [19]. F-1-P is then cleaved by aldol se B
into dihydroxyacetone phosphate and glyceraldehyde. Glyceraldehyde is phosphorylated by triokinase
generating glyceraldehyde 3-phosphate (GAP). GAP and other triose phosphates are resynthesized
into glucose via gluconeogenesis or metabolized into lactate or acetyl-CoA, which are oxidized or
used for lipogenesis. In the liver, fructose activates the transcription factors carbohydrate-responsive
element-binding protein (ChREBP) and sterol regulatory element-binding transcription factor 1c
(SREBP1c) and their coactivator peroxisome proliferator-activated receptor-β (PGC1β) [16]. This results
in upregulation of pathways that stimulate fructolysis, glycolysis, lipogenesis, and glucose production.
Collectively, this results in increased hepatic glucose production, generation of lipid intermediates
that may affect hepatic insulin sensitivity, increased expression of APOC3 and increased secretion
of triglyceride-rich very-low density lipoproteins (VLDL). The increased APOC3 expression induces
increased plasma apoC-III, an inhibitor of lipoprotein lipase and hepatic clearance of lipoprotein
remnants [20]. This results in hypertriglyceridemia and accumulation of atherogenic triglyceride-rich
lipoprotein (TRL) remnants.
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Carbohydrate response element binding protein (ChREBP), a transcription factor responding to
sugar intake, is recognized to be a key regulator of hepatic carbohydrate and lipid metabolism [21,22].
Recent data highlight the role of ChREBP in enterocytes as a regulator of intestinal GLUT-5
expression [19,23]. Interestingly, chronic fructose feeding in hamsters enhances lipid synthesis in
enterocytes, resulting in increased synthesis of apoB48 and release of intestinal-derived chylomicrons,
likely by activation of ChREBP and GLUT-5 [24]. In contrast, ChREBP-deficient mice fed a high
fructose diet are reported to be fructose intolerant due to impaired fructose absorption and decreased
expression of GLUT-5 [19]. These data highlight the role of intestinal ChREBP for fructose-induced
impaired metabolism.
The liver is considered to be the major organ for fructose metabolism [16,25–27]. Plasma concentration
of fructose are increased only trivially after fructose intake in humans as first pass metabolism by liver
covers about 80–90% of the fructose load. Recently, this concept has been challenged by studies in mice
utilizing isotope tracers and mass spectrometry [28]. The key finding suggests that the small intestine
may be the major site for dietary fructose metabolism instead of the liver. Notably, the intestinal
fructose metabolism seems to be a saturable process that allows high doses of dietary fructose to
pass to the liver. The handling of dietary fructose in humans may be different due to the relatively
smaller gut in humans than in mice [29]. This is supported by studies in healthy volunteers with
stable isotope-labelled fructose to study the initial metabolism of ingested fructose [30]. The amount
of dietary fructose escaping the splanchnic extraction averaged only about 14.5% and the first-pass
extraction was 85.5%.
A study in healthy males (n = 7) demonstrated that fructose combined with Intralipid infusion
(consisting of 10% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water) resulted
in increased apoB48 production rate without any altered catabolism of chylomicrons [31]. Recently,
we reported that in abdominally obese men, fructose consumption (75 g/per day served as fructose
sweetened beverage) for 12 weeks increased postprandial responses of both plasma triglycerides and
apoB48 to a fat rich meal [32]. How changes in fructose absorption and metabolism in enterocyte
influence intestinal lipogenesis, reflected in handling of dietary fats and postprandial lipemia, remains
to be established in future kinetic studies in humans as direct extrapolation from animal studies may
be misleading.
2.2. Fructose Metabolism in the Liver
Hepatic fructose and glucose metabolism occurs via divergent pathways with consequences on
hepatic lipid handling and insulin sensitivity reflected in metabolic diseases [15,27,33]. Fructose uptake
from portal circulation into liver is mediated by GLUT2 via first pass metabolism by phosphorylation
of fructose to fructose-1-phosphate, that is further metabolized to dihydroxyacetone phosphate and
glyceraldehyde 3-phosphate. Notably only a small part of ingested fructose ends up in the circulation
in contrast to glucose. These initial steps in fructose metabolism seem to be unregulated and bypass
the hormonal control in contrast to the strictly regulated glucose uptake and glycolysis in the liver
where insulin plays a central role. Glyceraldehyde 3-phosphate and other triose phosphate compounds
derived from fructolysis are directed to the formation of pyruvate and acetyl-CoA and to lipogenesis.
Consequently, fructose has effects on both glucose homeostasis and lipogenesis the partitioning
depending on cellular energy needs [34].
2.3. Evidence Linking Fructose Intake to Non-Alcoholic Fatty Liver Disease (NAFLD) and to Increased
Cardiometabolic Risk
The heterogeneity of obesity and its consequences on cardiometabolic risk has been addressed in
several outstanding recent reviews that have recognized the importance of body fat distribution, in
particular the ectopic fat in the liver as the critical link to cardiometabolic health [25,35–40]. The central
role of non-alcoholic fatty liver disease (NAFLD) as the source for multiple cardiometabolic risk factors
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has raised the questions how the liver can handle extra influx of lipids and the consequences on
lipoprotein metabolism and ultimately vascular health [9,10,13,41].
2.4. Effects of Fructose on Hepatic De Novo Lipogenesis
The hallmark of NAFLD is hepatic triglyceride accumulation. The disease develops when the
influx of lipid into the liver (from circulating non-esterified fatty acids, diet-derived chylomicrons, and
hepatic de novo lipogenesis(DNL)) exceeds hepatic lipid disposal (via β-oxidation in mitochondria and
triglyceride secretion as lipoprotein particles) [42]. In the past decade, we have seen a remarkable
increase in NAFLD [43–45]. It is already the most common cause of chronic liver disease in Western
countries and may soon achieve this status in the rest of the world.
Accumulating evidence indicates that increased hepatic DNL is a significant pathway contributing
to the development of NAFLD [6,46]. Dietary carbohydrates, in particular, fructose, have been shown
to stimulate DNL and increase liver fat, although it is still debated whether this is due to excess energy
or fructose per se [46]. Studies in humans are lacking but a comparison between fructose and glucose
supplementation in rats for two months showed that, although total caloric consumption was higher
in glucose-supplemented rats, fructose caused worse metabolic responses [47].
DNL is a highly regulated pathway, dependent upon several steps, in which key enzymes involved
are upregulated in NAFLD [48–50]. Importantly, dietary fructose further increases levels of enzymes
involved in DNL as fructose is absorbed via portal vein and delivered to the liver in much higher
concentrations as compared to other tissues. Interestingly, in contrast to metabolism of glucose, the
breakdown of fructose leads to the generation of metabolites that stimulate hepatic DNL [51–53].
Fructose drives lipogenesis in the setting of insulin resistance as fructose does not require
insulin for its metabolism, and it directly stimulates sterol regulatory element-binding protein 1
(SREBP-1c), a major transcriptional regulator of DNL (Figure 1) [54]. Fructose also promotes hepatic
DNL and lipid accumulation by suppressing hepatic β-oxidation and by inducing promotes ER
stress and uric acid formation (see below). High-fructose feeding has also been shown to increase
hepatic expression of ChREBP, a lipogenic transcription factor of carbohydrate metabolism and DNL.
ChREBP regulates fructose-induced glucose production independently of insulin signaling [22], and the
fructose-induced increases in circulating fibroblast growth factor 21 (FGF21) [55]. The fructose-induced
FGF21 feeds back on the liver to enhance further ChREBP activity and hepatic DNL and VLDL
secretion [55]. Consequently, circulating FGF21 levels correlate with rates of de novo lipogenesis in
human subjects [55]. FGF21 has also been implemented in a signaling axis regulating carbohydrate
consumption [11,16,27,33,46,56].
Despite convincing evidence in animals, whether fructose consumption increases DNL in humans
to the extent that it induces metabolic disturbances has been more controversial [57]. However,
Stanhope et al. reported that 10 weeks overfeeding of fructose (but not glucose), increased DNL (from
11% to 17%) [58]. Other studies have reported that a high fructose diet increased fasting DNL from 2%
to 9% [59], and that fructose (75 g/day), served with their habitual diet over 12 weeks to abdominally
obese men resulted in significant increases in DNL in both the fasting state (12.3% to 16.5%) and 4 to
8 h postprandially [32,60]. In line, 9 days of isocaloric fructose restriction in the context of an otherwise
normal diet led to significant decreased DNL in 37 out of 40 children with obesity [61].
2.5. Clinical Evidence That Fructose Consumption Is Leading to Non-Alcoholic Fatty Liver Disease (NAFLD)
As fructose is recognized to be a lipogenic sugar, its contribution to the pathogenesis of NAFLD
has been the focus of intensive research for more than a decade [16,27,33,54,58,62]. The ongoing interest
is stimulated by the huge global burden of NAFLD as the potential driver of CVD and its clinical
manifestations [11,15,16,63–65].
Although accumulated evidence has demonstrated a strong link between fructose consumption
and NAFLD it is still unclear if the association is caused by fructose consumption per se, or by the
increased energy intake [66]. An important reason for this is the technological problems associated with
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measuring liver fat content. Accurate non-invasively measurements of liver fat content require advanced
equipment like magnetic resonance imaging and spectroscopy [66–69]. Notably, these technologies
allow both quantitation and characterization of hepatic lipids [69,70]. NAFLD is commonly define as
>5.5% hepatic fat fraction as determined by MRI [71].
Mot studies focusing on the association between fructose or saccharose overfeeding and liver
fat steatosis (quantitated by MRI), have been performed in healthy or obese men [58,72–79]. Many of
these studies have been positive [58,72–79]. For example, daily intake of one liter regular cola for
6 months in overweight subjects (n = 10) was shown to associate with significant increases of liver
fat measured by MRI, but without significant changes of BMI or total fat mass [80]. However, many
studies have also been negative [81–83].
Reasons for the different outcome from these earlier studies are the relatively smaller study
cohorts, variable and short-duration less than 7 days) study designs, and differing doses of fructose.
Despite these weaknesses, many studies seem to indicate that hypercaloric fructose feeding increases
liver fat content and that this response is aggravated in obese subjects. For example, Ma et al. reported
that the regular consumption of SSBs in overweight and obese subjects from the Framingham cohort
(n = 2634) was associated with increases of liver fat content quantitated by computed tomography [84].
In line, we recently reported that fructose consumption (75 g/day as fructose sweetened beverage)
for 12 weeks in abdominally obese men with cardiometabolic risk factors, significantly increased liver
fat content measured by MRI despite relative low increases in weight and waist circumferences [32].
The study subjects were served their habitual diet with add on fructose feeding resulting in hypercaloric
set up that also occurs in the real world with SSB intake [32].
Despite this study design, the average increase of liver fat content was modest (10%) in face of no
significant change in visceral or subcutaneous fat depots and there was high variation in the response
liver fat content. To better understand this variation, we genotyped all individuals for carrier status of
the major risk alleles for hepatic steatosis; PNPLA3, TN6SF2, and MBOAT7. Results showed that the
number of risk alleles associated with increased liver fat at the baseline. However, individuals without
and with risk allele did not have differences in the response of liver fat during fructose feeding. In line
with this, two other studies have confirmed increases of liver fat content during carbohydrate (simple
sugars) overfeeding on hypercaloric diet for 3 weeks in overweight and obese subjects [85,86].
The key metabolic and mechanistic issues of fructose consumption has been studied during a
nine days isocaloric feeding study (fructose restriction to less than 4% of calories) in obese children
(n = 40) with MetS and a high habitual sugar consumption (>50 g/day) [61,87,88]. The metabolic
assessment was extensive utilizing magnetic resonance imaging and stable isotope technology for DNL
in addition to extensive biomarker platform. The first important message is that the dietary fructose
restriction was associated with significant reductions of liver (from 7.2% to 3.8%, p < 0.001) and visceral
fat content (from 123 cm3 to 110 cm3, p < 0.001). Notably, the reduction of liver fat content was not
related to the baseline liver fat content. The diet intervention was also associated with a significant
decrease of DNL and an improved lipoprotein profile. In addition, significant improvements were
observed in biomarkers of insulin resistance and glucose metabolism. The authors also elucidated the
impact of the diet intervention on the methylglyoxal (MG) pathway [15,63,89–91], and surprisingly
found that fructose restriction associated with marked reduction of D-lactate, a biomarker of MG
metabolism. This change of D-lactate correlated with reduction of liver fat content and DNL [88].
These observations open a new perspective of the adverse metabolic effects of excess fructose intake.
Thus, accumulating evidence supports the fact that fructose is an important mediator for the
development of NAFLD and a main driver for DNL [64]. Indeed, this concept is supported by a recent
meta-analysis including 6326 participants and 1361 cases with NAFLD [92]. However, it is still debated
whether fructose, when consumed in isocaloric amounts, causes more liver fat accumulation than other
energy-dense nutrients [93].
Kirk et al. investigated the effects of acute and chronic calorie restriction with either a low-fat,
high-carbohydrate (>180 g/day) diet or a low-carbohydrate (<50 g/day) diet on hepatic and skeletal
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muscle insulin sensitivity in 22 obese subjects [94]. Interestingly, the low-carbohydrate diet lowered
the hepatic lipids within 48 h by 30% (compared to ~10% in the low-fat, high-carbohydrate group).
The mechanism for the rapid clearance of liver fat was not elucidated. After approximately 11 weeks
(7% weight loss) a similar marked reduction of liver fat content was seen in both groups (38% vs. 44%).
These results show that liver fat content is highly dynamic in response to energy balance and sugar
intake. However, it is still debated whether a low-carbohydrate hypocaloric diet is more efficient than
a low-fat hypocaloric diet in reducing intrahepatic lipid accumulation.
Haufe et al. compared the 6 months responses of a low-carbohydrate hypocaloric or a low-fat
hypocaloric diet on intrahepatic lipid accumulation in overweight/obese subjects (n = 84 to 86 in
each group) [95]. Results showed that both diets had the same beneficial effects on intrahepatic lipid
accumulation, weight loss and insulin resistance. The decrease in intrahepatic fat was independent
of visceral fat loss and not associated with changes in whole body insulin sensitivity. Interestingly,
subjects with high baseline intrahepatic lipids (>5.6%) lost ≈ 7-fold more liver fat compared with those
with low baseline values irrespective of the prolonged hypocaloric diet.
2.6. Effects of Fructose on Uric Acid Metabolism and MG (Methyl Glyoxal) Pathways
The role of fructose as a potential source of uric acid was recognized decades ago [96]. The rapid
phosphorylation of fructose to fructose-1-phospate not only increases the fluxes of trioses for lipogenesis,
but also depletes ATP stores leading to the degradation of AMP, resulting in increased generation
of uric acid via purine pathway. Importantly, fructose seems to be the only carbohydrate that can
generate uric acid. Cellular depletion of ATP has several adverse consequences on energy metabolism
including increased ER stress and mitochondrial dysfunction [64]. ER stress has been linked to many
metabolic diseases including NAFLD [97] and can be induced by a range of condition such as high
protein demand, viral infection, mutant protein expression, hypoxia, energy deprivation, or exposure
to excessive oxidative stress including ATP depletion [97–99]. The ER stress triggers an adaptive
signaling pathway known as the Unfolded Protein Response (UPR) to restore normal ER function.
If the UPR fail to restore normal ER function, the UPR aims towards apoptosis [97–99]. A sustained
chronic UPR response may worsen the pathophysiological condition by inducing lipotoxicity, insulin
resistance, inflammation, and apoptotic cell death [97–99].
ER stress activates the transcription factor X-box binding protein 1 (XBP1s), a key regulator of
the unfolded protein response. Interestingly, XBP1 also regulates hepatic fatty acid synthesis [100].
Mitochondrial oxidative stress results in enhanced generation of citrate and acetyl coenzyme A
AcCoA [101–103], two metabolites that stimulate lipogenesis. This may explain why fructose is
lipogenic [16,104]. An additional nexus is that increased triose flux enhance the generation of methyl
glyoxal (MG) and dicarbonyl stress. A key crossroad step is the inactivation of AMPK by MG and
consequences on energy metabolism. This is a novel pathway linked to excess fructose intake and
its metabolic relevance remains to be clarified [15]. In summary, fructose seems to influence multiple
metabolic pathways in the liver that results in enhanced lipogenesis, generation of uric acid, ER stress,
and inflammation. The association between uric acid and insulin resistance [105], raised the interest
of uric acid as a potential biomarker in the Metabolic Syndrome [105]. Indeed, several studies have
established that serum uric acid is a risk factor for the Metabolic Syndrome [106–113].
Substantial evidence suggest that uric acid also associates with NAFLD [114–117]. Several studies
have reported that serum uric acid levels are higher in subjects with NAFLD than in those without
NAFLD [64,118,119]. Importantly, hyperuricemia seems to associate with NAFLD independently of
other features of the MetS and these associations are independent on body weight [120]. Thus, uric
acid belongs to the cluster of biomarkers in Metabolic Syndrome and NAFLD.
Can excess intake of fructose and SSBs result in the elevation of plasma uric acid concentrations?
Indeed, numerous studies have found an association between fructose/SSBs intake and uric acid
levels [27,54,64,118,121,122]. For example, two large prospective cohort studies including American
men (n = 46,393) or American women (n = 78,906) showed strong associations between consumption
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of SBBs and hyperuricemia [123,124]. Similar positive associations between SSBs intake and serum
uric acid concentrations have been observed in Korean, Mexican, and Brazilian populations [125–127].
Likewise, in an adolescents cohort (n = 4867 aged 12 to 18 years) consumption of SSBs associated with
higher serum uric acid and also higher systolic blood pressure [128].
So far, data from RCTs on fructose feeding trials have remained limited. Fructose feeding associated
with increased uric acid in three smaller intervention studies [72,129,130]. Weaknesses of the study
protocol are that the design and duration of feeding trials, as well as study cohorts, are highly variable.
Unfortunately, data from available meta-analyses are not consistent. One meta-analysis reported
that fructose intake as an apart of isocaloric diet did not raise uric acid levels but signaled that the
hypercaloric intake of fructose may raise uric acid [131]. Although hyperuricemia is highly prevalent
in patients with NAFLD and Met Syndrome, its clinical relevance remains debated. Recent French
recommendations for sugar intake concluded that long-term consequences of potential small increases
of uric acid by fructose/sugar intake remain insufficient [132], likewise critical analysis of the available
data left open the casual link between fructose intake and hyperuricemia [133,134].
2.7. Consequences of Increased Lipid Synthesis to Very Low-Density Lipoproteins (VLDL) Metabolism and
Release—Effects on Plasma Lipids, Lipoproteins, and Apolipoproteins
The association of blood lipid levels and consumption of added sugars was studied in the adult
population in the National Health and Nutrition Examination Survey (NHANES) (n = 6113) [135].
In this American cross-sectional study higher fructose consumers had more unfavorable lipid levels,
namely significantly lower HDL cholesterol, higher triglycerides, and a high ratio of triglycerides
to high density lipoproteins (HDL), whereas women also had higher low-density lipoprotein (LDL)
cholesterol levels. Likewise, in the Framingham study, daily soft drink consumers had higher incidence
of elevated triglycerides and low HDL cholesterol than non-consumers (relative risk: 1.22 and 1.22,
respectively) [136].
Several studies have consistently reported increased responses of fasting and postprandial
triglyceride levels and 24 h. profiles to short term feeding of fructose as compared to glucose in both
lean and obese subjects [8,53]. These perturbations directly lead to other lipid abnormalities including
elevation of apoB levels, accumulation of small dense LDL, and increased remnant lipoproteins,
combined with reduced HDL cholesterol which all are components of the atherogenic lipid triad,
a strong risk factor for CVD. Interestingly, the deleterious effect of fructose on lipid metabolism is directly
linked to the daily intake; a fructose intake >50 g/day is associated with postprandial hyperlipemia
whereas intake above 100 g/day also results in elevation of fasting serum triglycerides [137]. Collectively,
these results clearly show that fructose intake is directly linked to an atherogenic dyslipidemia.
The recent increased focus on plasma triglycerides and postprandial hyperlipidemia not only as
markers but also as causal drivers of CVD has partly been driven by improved understanding of the
biology and genetics of triglyceride heritability. Of particular interest is APOC3, which has emerged as
a novel therapeutic target to reduce dyslipidemia and CVD risk [20,138–140]. Interestingly, fructose
feeding is linked to a significant rise of plasma apoC-III levels (Figure 1) [32,141].
2.8. Interactions between Fructose Consumption and Changes in Gut Microbiota
High consumption of fructose, artificial sweeteners, and sugar alcohols have been shown to affect
host-gastrointestinal microbe interactions and possibly contribute to the development of metabolic
disorders and obesity. Multiple studies have also reported fructose as a critical factor contributing
to NAFLD progression by modulating intestinal microbiota (see review [142]). Gut microbiota
interacts with its host, and influences both the energy homeostasis and the immunity of the host [142].
Shifts in this composition can result in alterations of the symbiotic relationship, which can promote
metabolic diseases [143]. Indeed, the microbial composition have been shown to differ between healthy
individuals and NAFLD patients [144], and a diet enriched in fructose not only induced NAFLD
but also negatively affected the gut barrier and the microbiota composition, leading to impaired
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microbiota [145]. The underlying mechanisms are complex and still unclear, but Oh et al. recently
showed that dietary fructose activates the Ack-pathway, involved in generating acetic acid, which in
turn triggers the bacterial stress response that promotes phage production [146]. Thus, prophages in
a gut symbiont can be induced by diet and metabolites affected by diet, which provides a potential
mechanistic explanation for the effects of diet on the intestinal phage community [147].
The complex interaction between dietary carbohydrates and gut microbiota was recently
demonstrated in a two-week intervention with an isocaloric low-carbohydrate diet in obese subjects
with NAFLD [148]. The authors observed rapid and marked reductions of liver fat paralleled by
marked decreases in hepatic DNL and increases in hepatic β-oxidation. Interestingly, the marked
reduction in cardiometabolic risk factors paralleled with rapid increases in the folate-producing gut
microbiota Streptococcus, serum folate concentrations, and hepatic one-carbon metabolism.
3. Conclusions
Consistent data evidence that excess fructose intake as a central component of unhealthy lifestyle
has detrimental effects on multiple cardiovascular risk factors. Consequently, it is not surprising that
links between fructose consumption with MetS and NAFLD are strong. Fructose is a lipogenic sugar
as it increases hepatic de novo lipogenesis in the liver through several metabolic pathways resulting
in a vicious circle that further aggravates DNL. Increased DNL favors excess fat accumulation in the
liver, being a driving force for increased secretion of VLDL particles leading to the atherogenic lipid
profile and other metabolic derangements associated with CVD risk. The global health burden of MetS
together with NAFLD is growing rapidly, sweeping across the world. It is clear that added sugars
have become a threat to cardiometabolic health. These facts call for the restriction of dietary sugars,
especially SSB consumption to limit fructose intake to achieve better cardiometabolic health.
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